11 Results for "

Pyrazolopyrimidines

" in MedChemExpress (MCE) Product Catalog:
Products (11)

11 Results for "Pyrazolopyrimidines" in MCE Product Catalog:

3
3 Cited Publications
Cat. No.: HY-10520
CAS No.: 522629-08-9
Purity:  98.71%
Target:  

MNK Apoptosis

Research Areas:  

Cancer

CGP 57380 is a cell-permeable pyrazolo-pyrimidine compound that acts as a selective inhibitor of Mnk1 with IC50 of 2.2 μM, but has no inhibitory activity against p38, JNK1, ERK1/2, PKC, or Src-like kinases.
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-117596
CAS No.: 1350547-65-7
Purity:  99.92%
Target:  

TAM Receptor

Research Areas:  

Cancer

UNC569 is a potent, reversible, ATP-competitive and orally active Mer kinase inhibitor with an IC50 of 2.9 nM and a Ki of 4.3 nM. UNC569 also inhibits Axl and Tyro3 with IC50s of 37 nM and 48 nM, respectively. UNC569 can be used for acute lymphoblastic leukemia (ALL) and atypical teratoid/rhabdoid tumors research
loading...
    loading...
Cat. No.: HY-153246
CAS No.: 2414149-20-3
Research Areas:  

Cancer

ALK2-IN-5, pyrazolopyrimidine compound, is an ALK2 inhibitor. ALK2-IN-5 can inhibit ALK2 activity and FGFR activity. ALK2-IN-5 can be used for the research of disorders associated with ALK2 activity and/or FGFR activity, such as cancer .
loading...
    loading...
Cat. No.: HY-117882
CAS No.: 147676-50-4
Synonyms: Piperidino-acetildenafil
Target:  

Drug Intermediate

Research Areas:  

Others

Piperiacetildenafil (compound 3) is an intermediate for the preparation of pyrazolopyrimidines .
loading...
    loading...
Cat. No.: HY-163725
Research Areas:  

Cancer

DHFR-IN-18 (compound 19D) is a DHFR inhibitor. DHFR-IN-18 can be used in anti-leukemia research .
loading...
    loading...
Cat. No.: HY-150573
CAS No.: 2410402-88-7
Target:  

CDK Carbonic Anhydrase

Research Areas:  

Cancer

CDK2-IN-12 (compound 10b) is a potent CDK2 inhibitor, with an IC50 of 11.6 μM. CDK2-IN-12 inhibits hCA (carbonic anhydrase) isoforms I, II, IX and XII, with KI values of 3534, 638.4, 44.3, and 48.8 nM. CDK2-IN-12 shows anticancer activity .
loading...
    loading...
Cat. No.: HY-157487
Target:  

Drug Derivative

Research Areas:  

Cancer

Anticancer agent 185 (compound 9d) is a glycohybrid derivative of pyrazolopyrimidine [1,5-a]. Anticancer agent 185 has good anti-breast cancer activity. Anticancer agent 185 shows good cytotoxic activity against MCF-7 cells with IC50 value of 15.3 μM .
loading...
    loading...
Cat. No.: HY-164413
CAS No.: 1312024-59-1
Target:  

VEGFR EGFR RET Apoptosis

Research Areas:  

Cancer

CLM3, a pyrazolopyrimidine derivative, is a multiple tyrosine kinase inhibitor. CLM3 shows antiproliferative and proapoptotic activity on endothelial and cancer cells, synergistically enhanced by SN38 (HY-13704). These effects are mainly due to its inhibition of phosphorylation of VEGFR-2, EGFR and RET tyrosine kinases and their related signaling pathways .
loading...
    loading...
Cat. No.: HY-163267
Target:  

Fluorescent Dye

Research Areas:  

Others

ZNL0325 is a covalent probe based on pyrazolopyrimidine. ZNL0325 features an acrylamide side chain at the C3 position, which is capable of forming covalent bonds with multiple kinases that possess a cysteine at the αD-1 position, including BTK, EGFR, BLK, and JAK3. ZNL0325 can be used in the research of creating structurally distinct covalent kinase inhibitors .
loading...
    loading...
Cat. No.: HY-147565
CAS No.: 2758113-84-5
Target:  

ATM/ATR

Research Areas:  

Cancer

ATR-IN-13 (compound A9) is a potent ATR kinase inhibitor, with an IC50 of 2 nM. ATR-IN-13 can be used for ATR kinase mediated diseases research, such as proliferative diseases and cancer .
loading...
    loading...
Cat. No.: HY-10520R
CAS No.: 522629-08-9
Research Areas:  

Cancer

CGP 57380 (Standard) is the analytical standard of CGP 57380 (HY-10520). This product is intended for research and analytical applications. CGP 57380 is a cell-permeable pyrazolo-pyrimidine compound that acts as a selective inhibitor of Mnk1 with IC50 of 2.2 μM, but has no inhibitory activity against p38, JNK1, ERK1/2, PKC, or Src-like kinases.
loading...
    loading...
  • 1